Spokesperson for the Covid-19 Vaccine from the Ministry of Health (Kemenkes) Siti Nadia Tarmizi confirmed that the type or brand that will be used for the initial stage of the corona virus (Covid-19) vaccine injection program in Indonesia is made by a Chinese company, Sinovac.
Nadia explained, currently Indonesia has recorded 3 million doses of the Covid-19 vaccine from Sinovac which were imported in two shipments. First, on December 6, 2020 there were 1.2 million doses, and on December 31, 2020 there were 1.8 million doses.
“So, use Sinovac, which was there first, for the initial vaccination of the health workers,” said Nadia .
Nadia explained that the most data on the distribution of health workers (health workers) was in Central Java with 177,784 people, followed by West Java with 161,143 people, then East Java with 131,997 people.
Then those in the third lowest rank of the distribution of health workers are Gorontalo with 7,134 people, West Sulawesi 5,705 people, and North Kalimantan 4,949 people.
Nadia emphasized that the vaccination target data is still dynamic and tends to increase. The reason is, according to the recommendations of the World Health Organization (WHO) each person needs two doses of vaccine. Thus, 3 million Sinovacs are able to target 1.5 million people.
“There are 1.3 million health workers in 34 provinces, yes, so it is the initial stage for all medical personnel in Indonesia, maybe even more, yes, there are volunteers, like that,” said Nadia.
“There is more than that target for the buffer stock,” he added.
The 3 million doses of the vaccine have entered the distribution process to 34 Indonesian Provinces since last Sunday (3/1). However, the Food and Drug Supervisory Agency (BPOM) has yet to receive interim clinical trial data from the FK Unpad team so that it has not been able to issue an emergency use authorization (EUA).
Contacted separately, the Field Manager of the Covid-19 Vaccine Clinical Trial Research Team from the Faculty of Medicine, Eddy Fadlyana, promised to submit the three-month interim report to BPOM this week.
“On January 8th we submitted [interim report] to BPOM,” said Eddy
Eddy explained that the three-month report was the result of a study containing safety data on clinical trial subjects who were observed after two injections; data on immunogenicity or the ability of the vaccine to form antibodies; and data on vaccine efficacy or vaccine ability to protect people exposed to the virus from becoming sick.
And in the quarterly report, his party only included as many as 540 people or a sample of a total of 1,620 clinical trial volunteers as a whole.
Regarding EUA, the Spokesperson for Vaccination from BPOM Lucia Rizka Andalusia previously also explained that according to WHO policy, the ingredients that will be used as efficacy calculations are the results of phase I and II clinical trials, as well as the results of stage III interim clinical trials.
The interim phase III clinical trial is the result of monitoring the efficacy during the first three months of the vaccine being injected into volunteers.
However, Lucia emphasized that clinical trials will continue after the EUA administration until the next six months of observation. He also admitted that the standards used by BPOM in establishing EUA did not run away from the standards previously set by the United States BPOM (FDA) and Europe (EMA).